We’re proud to announce a deployment of
#MSIcare at CHU Rennes, one of France’s university hospitals.
The objective: evaluate MSIcare directly within their NGS sequencing infrastructure, under real-world clinical conditions.
This is exactly where precision diagnostics needs to be tested – not just in theory, but in the hands of the teams who use it daily.
🗣️ »We are committed to evaluating innovative tools that can improve diagnostic precision for our patients. MSIcare is a solution for microsatellite instability detection directly from NGS data, designed to integrate into existing sequencing workflows. Integrating MSI detection directly from NGS data could streamline workflows and support more timely therapeutic decisions. » – Alexandra Lespagnol, Analytical Development & Innovation Lead, Somatic Cancer Genetics Laboratory, CHU Rennes
🗣️ »Partnering with CHU de Rennes is a milestone for MSInsight. Having MSIcare tested in real clinical settings, by expert teams, is the strongest validation path we can pursue. This is how we build trust and adoption. » – Arnaud Cutivet, CEO, MSInsight
This marks a key step in our clinical deployment strategy across France and Europe.
More to come.
